Accrued expenses consisted of the following (in thousands): | | | | | | | | | | June 30, | | December 31, | | | | 2024 | | 2023 | | Payroll and related costs | | $ | 3,783 | | $ | 7,746 | | Clinical trials and drug development | | | 3,764 | | | 4,701 | | Accrued license agreement payment | | | — | | | 4,000 | | Professional fees | | | 1,269 | | | 1,236 | | Selling and commercial liabilities | | | 4,475 | | | 3,901 | | Restructuring costs | | | 952 | | | — | | Short-term lease liabilities | | | 778 | | | 774 | | Other | | | 210 | | | 501 | | Total accrued expenses | | $ | 15,231 | | $ | 22,859 | |
|